EUVIMEDEUVIMED entdecken
Crossref

Clinical profile, treatment and quality of life of patients with psoriatic arthritis in Malaysia: A population‐based cross‐sectional study

Shiau Fui Goh iD, Siu Bee Wong, Suganthy Robinson iD, Min Moon Tang

Experimental Dermatology · 2024

DOI: 10.1111/exd.15060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2024. Verfasst von Shiau Fui Goh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Kuala Lumpur, Ministry of Health Malaysia, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Psoriasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriatic arthritis (PsA) is a major comorbidity of psoriasis and may lead to irreversible joint damage and disability. This study aims to describe the clinical profile, treatment and quality of life (QoL) of patients with PsA in Malaysia. This is a multicentre retrospective cross‐sectional study of psoriasis patients who were notified to the Malaysian Psoriasis Registry (MPR) from January 2007 to December 2018. Of 21 735 psoriasis patients, 2756 (12.7%) had PsA. The male to female ratio was 1:1. The mean age of psoriasis onset for PsA patients was 34.73 ± 14.44 years. They had a higher rate of family history of psoriasis (26% vs. 22.4%, p < 0.001), scalp (82.7% vs. 81.0%, p = 0.04) and nail involvement (73.3% vs. 53.3%, p < 0.001), obesity (62.6% vs. 54.4%, p < 0.001), dyslipidaemia (23.8% vs. 15.4%, p < 0.001), hypertension (31.1% vs. 22.7%, p < 0.001) and diabetes mellitus (20.9% vs. 15.2%, p < 0.001) compared to non‐PsA patients. More than half (54.3%) had severe psoriasis [(body surface area >10% and/or Dermatology Life Quality Index (DLQI) >10)]. Most had oligo‐/monoarthropathy (40.3%), followed by distal interphalangeal arthropathy (31.3%), symmetrical polyarthropathy (28.3%), spondylitis/sacroiliitis (8.2%) and arthritis mutilans (3.2%). Nearly 40% of PsA patients received systemic treatment, but only 1.6% received biologic agents. QoL was more significantly affected in PsA than in non‐PsA patients (mean DLQI 10.12 ± 7.16 vs. 9.52 ± 6.67, p < 0.001). One in eight patients with psoriasis in Malaysia had PsA. They had a higher incidence of comorbidities, severe disease, impaired QoL and were more likely to receive systemic and biological treatment compared to non PsA patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticPsoriasisHumansMaleFemaleYoung AdultAdultMiddle AgedQuality of LifeCross-Sectional StudiesMalaysiaRetrospective Studies

Stichwörter der Autor:innen

inflammatory arthritispsoriasispsoriatic arthritisquality of life

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Kuala Lumpur, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
  • Department of Dermatology, Hospital Sultanah Bahiyah, Ministry of Health Malaysia, Alor Setar, Malaysia.

ORCID-Profile: Shiau Fui Goh, Suganthy Robinson

Zitieren

APA

Goh, S. F., Wong, S. B., Robinson, S., & Tang, M. M. (2024). Clinical profile, treatment and quality of life of patients with psoriatic arthritis in Malaysia: A population‐based cross‐sectional study. Experimental Dermatology. https://doi.org/10.1111/exd.15060

Vancouver

Goh SF, Wong SB, Robinson S, Tang MM. Clinical profile, treatment and quality of life of patients with psoriatic arthritis in Malaysia: A population‐based cross‐sectional study. Experimental Dermatology. 2024. doi:10.1111/exd.15060

BibTeX
@article{Goh2024,
  author = {Goh, Shiau Fui and Wong, Siu Bee and Robinson, Suganthy and Tang, Min Moon},
  title = {Clinical profile, treatment and quality of life of patients with psoriatic arthritis in Malaysia: A population‐based cross‐sectional study},
  journal = {Experimental Dermatology},
  year = {2024},
  doi = {10.1111/exd.15060}
}
Kostenlos starten →